title: Arming antibodies: prospects and challenges for immunoconjugates.
abstract: Immunoconjugates--monoclonal antibodies (mAbs) coupled to highly toxic agents, including radioisotopes and toxic drugs (ineffective when administered systemically alone)--are becoming a significant component of anticancer treatments. By combining the exquisite targeting specificity of mAbs with the enhanced tumor-killing power of toxic effector molecules, immunoconjugates permit sensitive discrimination between target and normal tissue, resulting in fewer toxic side effects than most conventional chemotherapeutic drugs. Two radioimmunoconjugates, ibritumomab tiuxetan (Zevalin) and tositumomab-131I (Bexxar), and one drug conjugate, gemtuzumab ozogamicin (Mylotarg), are now on the market. For the next generation of immunoconjugates, advances in protein engineering will permit greater control of mAb targeting, clearance and pharmacokinetics, resulting in significantly improved delivery to tumors of radioisotopes and potent anticancer drugs. Pre-targeting strategies, which separate the two functions of antibody-based localization and delivery or generation of the toxic agent into two steps, also promise to afford superior tumor targeting and therapeutic efficacy. Several challenges in optimizing immunoconjugates remain, however, including poor intratumoral mAb uptake, normal tissue conjugate exposure and issues surrounding drug potency and conditional release from mAb carriers. Nonetheless, highly promising results from preclinical models will continue to drive the clinical development of this therapeutic class.
authors.affiliation: Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at University of California, Los Angeles, Box 951770, 700 Westwood Plaza, Los Angeles, California 90095, USA. awu@mednet.ucla.edu
authors.forename: Anna M
authors.initials: AM
authors.lastname: Wu
authors.forename: Peter D
authors.initials: PD
authors.lastname: Senter
mesh_terms: D000617:Aminoglycosides / Q000494:pharmacology; D000818:Animals; D000906:Antibodies / Q000737:chemistry*; D000911:Antibodies, Monoclonal / Q000737:chemistry* / Q000494:pharmacology; D061067:Antibodies, Monoclonal, Humanized; D001709:Biotechnology / Q000379:methods / Q000639:trends*; D019921:Biotinylation; D000079982:Gemtuzumab; D006801:Humans; D018796:Immunoconjugates / Q000737:chemistry*; D007128:Immunoglobulin Fragments / Q000737:chemistry; D007167:Immunotherapy / Q000379:methods*; D008956:Models, Chemical; D009369:Neoplasms / Q000378:metabolism / Q000628:therapy; D011355:Prodrugs / Q000494:pharmacology; D015202:Protein Engineering; D016499:Radioimmunotherapy / Q000379:methods; D011868:Radioisotopes / Q000737:chemistry; D013997:Time Factors
chemical_list: D000617:Aminoglycosides; D000906:Antibodies; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018796:Immunoconjugates; D007128:Immunoglobulin Fragments; D011355:Prodrugs; D011868:Radioisotopes; C422802:ibritumomab tiuxetan; D000079982:Gemtuzumab; C119496:tositumomab I-131